|
|
- For a short-term investment strategy, the company has poor fundamentals.
|
|
|
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Historically, the company has been releasing figures that are above expectations.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
|
|
|
- Technically, the stock approaches a strong medium-term resistance at USD 5.83.
- Low profitability weakens the company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
|
|
|
|
|
| Sector Bio Therapeutic Drugs |
|
| | 1st jan. | Capitalisation (M$) | Investor Rating |
 |
 | EVOLUS, INC. | 72.32% | 195 | |
| |
|
|
|
| Sales 2020 |
58,0 M
-
-
|
| Net income 2020 |
-65,9 M
-
-
|
| Net Debt 2020 |
-
-
-
|
| P/E ratio 2020 |
-2,97x |
| Yield 2020 |
- |
|
| Capitalization |
195 M
195 M
-
|
| Capi. / Sales 2020 |
3,37x |
| Capi. / Sales 2021 |
2,22x |
| Nbr of Employees |
125 |
| Free-Float |
66,0% |
|
Upcoming event on EVOLUS, INC.
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
- |
| Finances |
- |
| Profitability |
|
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
- |
| Potential |
|
| Yield |
- |
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
